Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-X<sub>L</sub>, in patients with cancer - Concepedia

Concepedia

Publication | Closed Access

Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-X<sub>L</sub>, in patients with cancer

13

Citations

12

References

2014

Year

Jiaji Yang, R. Pradhan, Lee S. Rosen, Alison M. Graham, Kyle D. Holen, Hao Xiong

Journal of Clinical Pharmacy and Therapeutics

Abstract

Co-administration navitoclax with rifampin moderately decreased navitoclax AUC, which could be partly due to the induction effect of rifampin on CYP3A4. Further assessment on the mechanism of drug interaction is warranted.

References

	Year	Citations

Page 1